Research Paper Volume 14, Issue 2 pp 907—922
A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment
Figure 8. Survival analyses in different groups of disease progression risk classified by the radiomics model. (A) Progression-free survival (PFS) in different groups of disease progression risk. (B) Overall survival (OS) in different groups of disease progression risk.